<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05622123</url>
  </required_header>
  <id_info>
    <org_study_id>NL81554.091.22</org_study_id>
    <nct_id>NCT05622123</nct_id>
  </id_info>
  <brief_title>BetaFIT Study: Beta Cell Imaging After Faecal mIcrobiota Transplantation</brief_title>
  <acronym>BetaFIT</acronym>
  <official_title>The Effects of Faecal Microbiota Transplantation on Beta Cell Preservation in Patients With Newly Diagnosed Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal is to investigate whether beta cell mass is correlated to beta cell function&#xD;
      after autologous faecal microbial transplantation (FMT) in patients with newly diagnosed type&#xD;
      1 diabetes&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The incidence of Type 1 Diabetes Mellitus (T1D) has tripled in the last thirty years, and T1D&#xD;
      is associated with a lifelong increase of considerable morbidity and mortality compared to&#xD;
      healthy subjects. As the increased T1D incidence is primarily observed in subjects who are&#xD;
      not genetically predisposed, environmental factors including altered diet, antibiotic use as&#xD;
      well as mode of birth have been suggested to play a role, and these factors have invariably&#xD;
      been linked to changes in the gut microbiome. Indeed, an altered composition of the faecal&#xD;
      microbiota composition was observed in adolescent T1D patients. A previous study by de Groot&#xD;
      et al. (2021) showed that faecal microbiota transplantation stops the decline in endogenous&#xD;
      insulin production in newly diagnosed type 1 diabetes patients. However, it is unknown&#xD;
      whether this is due to an increase in beta cell mass, or increased function of the remaining&#xD;
      beta cells.&#xD;
&#xD;
      In this study, the investigators aim to investigate whether beta cell mass (quantified by&#xD;
      68Ga-NODAGA-exendin-4 PET/CT imaging) is correlated to beta cell function after autologous&#xD;
      faecal microbial transplantation in patients with newly diagnosed type 1 diabetes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2023</start_date>
  <completion_date type="Anticipated">March 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between residual beta cell mass and function</measure>
    <time_frame>1 year</time_frame>
    <description>The correlation between residual beta cell mass measured with 68Ga-NODAGA-Exendin-4 PET/CT imaging at 12 ±1 months and beta cell function derived in the ENCAPSULATE-DM1 or FMT preserve-DM1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation with other parameters</measure>
    <time_frame>1 year</time_frame>
    <description>Beta cell mass will be related to parameters derived in the ENCAPSULATE-DM1 or FMT preserve-DM1 study (e.g. immunity status, insulin sensitivity)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Patients with type 1 diabetes who have completed the ENCAPSULATE-DM1 or FMT preserve-DM1 trial</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PET/CT imaging after injection with 68Ga-NODAGA-exendin-4 to quantify beta cell mass</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68Ga-NODAGA-Exendin-4</intervention_name>
    <description>PET/CT imaging after injection with 68Ga-NODAGA-exendin-4</description>
    <arm_group_label>Patients with type 1 diabetes who have completed the ENCAPSULATE-DM1 or FMT preserve-DM1 trial</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previously participated in ENCAPSULATE-DM1 or FMT preserve-DM1 trial&#xD;
&#xD;
          -  Type 1 diabetes with the diagnosis being made in the last 4.5 years&#xD;
&#xD;
          -  Presence of at least one autoantibody associated with type 1 diabetes (anti-GAD-65,&#xD;
             anti-IA2, islet cell antibodies, insulin autoantibodies)&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  BMI 18-30 kg/m2&#xD;
&#xD;
          -  Insulin use&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to provide written informed consent&#xD;
&#xD;
          -  Other medication use than insulin&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Evidence of compromised immunity&#xD;
&#xD;
          -  Presence of a second autoimmune disease (other than type 1 diabetes); e.g. celiac&#xD;
             disease, hyper- or hypothyroidism, inflammatory bowel disease. Vitiligo is allowed.&#xD;
&#xD;
          -  Pregnancy or the wish to become pregnant within 1 month after the study&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Liver disease defined as aspartate aminotransferase or alanine aminotransferase level&#xD;
             of more than three times the upper limit of normal range&#xD;
&#xD;
          -  Renal disease defined as MDRD &lt; 40 ml/min/1.73 m²&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Gotthardt, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sevilay Tokgöz, PhD student</last_name>
    <phone>+312455340</phone>
    <email>sevilay.tokgoz@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Gotthardt, MD, Prof.</last_name>
    <email>martin.gotthardt@radboudumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sevilay Tokgöz, PhD student</last_name>
      <phone>+312455340</phone>
      <email>sevilay.tokgoz@radboudumc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 8, 2022</study_first_submitted>
  <study_first_submitted_qc>November 17, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2022</study_first_posted>
  <last_update_submitted>April 3, 2023</last_update_submitted>
  <last_update_submitted_qc>April 3, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Faecal microbiota transplantation</keyword>
  <keyword>GLP-1 receptor</keyword>
  <keyword>exendin</keyword>
  <keyword>beta cell mass</keyword>
  <keyword>beta cell function</keyword>
  <keyword>imaging</keyword>
  <keyword>microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

